Alzamend Neuro Overview

  • Founded
  • 2016

Founded
  • Status
  • Public

  • Employees
  • 8

Employees
  • Stock Symbol
  • ALZN

Stock Symbol
  • Share Price
  • $1.08

  • (As of Friday Closing)

Alzamend Neuro General Information

Description

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 3802 Spectrum Boulevard
  • Suite 112C
  • Tampa, FL 33612
  • United States
+1 (844) 000-0000

Alzamend Neuro Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alzamend Neuro Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.08 $1.21 $0.80 - $3.57 $116M 95.5M 464K -$0.15

Alzamend Neuro Financials Summary

In Thousands,
USD
TTM 31-Jul-2022 FY 2022 30-Apr-2022 FY 2021 30-Apr-2021 FY 2020 30-Apr-2020
EV 70,829 83,089
Revenue 0 0 0 0
EBITDA (13,045) (12,312) (4,889) (4,424)
Net Income (13,079) (12,362) (5,047) (4,410)
Total Assets 12,210 14,516 2,913 1,814
Total Debt 0 0 335 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alzamend Neuro Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alzamend Neuro‘s full profile, request access.

Request a free trial

Alzamend Neuro Executive Team (5)

Name Title Board Seat Contact Info
Stephan Jackman Chief Executive Officer & Board Member
David Katzoff Chief Financial Officer, Finance
Henry Nisser Board Member & Executive Vice President
Kenneth Cragun Senior Vice President
You’re viewing 4 of 5 executive team members. Get the full list »

Alzamend Neuro Board Members (6)

Name Representing Role Since
Henry Nisser Self Board Member & Executive Vice President 000 0000
Mark Gustafson Self Board Member 000 0000
Milton Ault III Self Chairman & Board Member 000 0000
Philip Mansour Alzamend Neuro Board Member 000 0000
Stephan Jackman Alzamend Neuro Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Alzamend Neuro Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alzamend Neuro Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alzamend Neuro‘s full profile, request access.

Request a free trial